Characteristics | Total(n = 117) | Mono-CA-BSI(n = 93) | Mixed-CA/B-BSIs(n = 24) | Pvalue |
---|---|---|---|---|
Age, median years (IQR) | 68 (59,75) | 69 (59,76) | 64 (47,74) | 0.399 |
Male sex [n (%)] | 68 (58.1%) | 53 (56.9%) | 15 (62.5%) | 0.626 |
APACHE II score at the onset of candidemia (IQR) | 17.0 (11.5,24.5) | 17.0 (12.0,24.0) | 17.5 (10.0,26.5) | 0.863 |
SOFA score at the onset of candidemia (IQR) | 6.0 (2.0,9.0) | 5.0 (2.0,9.0) | 6.5 (2.0,9.8) | 0.494 |
Prior ICU stay (days) (IQR) | 3.0 (0.0,14.0) | 1.0 (0.0,11.0) | 12.0 (8.0,17.8) | 0.001 |
Prior hospital stay (days) (IQR) | 14.0 (4.5,27.5) | 12.0 (2.0,26.5) | 19.0 (12.0,30.8) | 0.031 |
Prior ventilation mechanical ventilation (days) (IQR) | 1.0 (0.0,13.0) | 1.0 (0.0,10.0) | 11.0 (0.3,24.5) | 0.013 |
Underlying disease [n (%)] | ||||
 Diabetes mellitus | 28 (23.9%) | 23 (24.7%) | 5 (20.8%) | 0.690 |
 Chronic cardiac dysfunction | 24 (20.5%) | 16 (17.2%) | 8 (33.3%) | 0.144 |
 Chronic obstructive pulmonary disease | 5 (4.3%) | 5 (5.4%) | 0 (0%) | 0.552 |
 Chronic renal insufficiency | 9 (7.7%) | 8 (8.6%) | 1 (4.2%) | 0.766 |
 Chronic hepatic insufficiency | 14 (12.0%) | 13 (14.0%) | 1 (4.2%) | 0.333 |
 Solid tumour | 33 (28.2%) | 28 (30.1%) | 5 (20.8%) | 0.368 |
 Haematological malignancy | 1 (0.9%) | 1 (1.1%) | 0 (0%) | > 0.999 |
 Trauma | 19 (16.2%) | 14 (15.1%) | 5 (20.8%) | 0.708 |
 Burn injury | 4 (3.4%) | 2 (2.2%) | 2 (8.3%) | 0.186 |
 Transplant | 14 (12.0%) | 11 (11.8%) | 3 (12.5%) | > 0.999 |
Immunocompromised [n (%)] | ||||
 Immunosuppressant therapy | 6 (5.1%) | 6 (6.5%) | 0 (0.0%) | 0.448 |
 Steroid therapy | 6 (5.1%) | 6 (6.5%) | 0 (0.0%) | 0.448 |
 Chemotherapy/radiation | 7 (6.0%) | 7 (7.5%) | 0 (0.0%) | 0.366 |
 Neutropenia | 4 (3.4%) | 3 (3.2%) | 1 (4.2%) | > 0.999 |
Blood transfusion [n (%)] | 40 (34.2%) | 30 (32.2%) | 10 (41.7%) | 0.386 |
Hospitalization ward [n (%)] | ||||
 Medical | 11 (9.4%) | 11 (11.8%) | 0 (0.0%) | 0.168 |
 Surgical | 28 (23.9%) | 24 (25.8%) | 4 (16.7%) | 0.349 |
 ICU | 78 (66.7%) | 58 (62.4%) | 20 (83.3%) | 0.052 |
Nosocomial infection [n (%)] | 112 (95.7%) | 88 (94.6%) | 24 (100%) | 0.552 |
Life-sustaining treatments ≥24 h [n (%)] | ||||
 Invasive mechanical ventilation | 65 (60.2%) | 47 (54.7%) | 18 (81.8%) | 0.020 |
 Vasopressor | 45 (38.5%) | 34 (36.6%) | 11 (45.8%) | 0.405 |
 CRRT | 30 (25.6%) | 20 (21.5%) | 10 (41.7%) | 0.044 |
Catheterisation a [n (%)] | ||||
 Central venous catheterb | 106 (90.6%) | 83 (89.2%) | 23 (95.8%) | 0.553 |
  Hemodialysis catheterc | 27 (23.1%) | 17 (18.3%) | 10 (41.7%) | 0.015 |
  PICC | 13 (11.1%) | 10 (10.8%) | 3 (12.5%) | > 0.999 |
  Peripheral arterial catheters | 37 (31.6%) | 29 (31.2%) | 8 (33.3%) | 0.840 |
 Drainage tube | 77 (65.8%) | 59 (63.4%) | 18 (75.0%) | 0.287 |
 Urethral catheter | 106 (90.6%) | 85 (91.4%) | 21 (87.5%) | 0.848 |
Presence of two or more central venous catheters | 36 (30.8%) | 24 (25.8%) | 12 (50.0%) | 0.022 |
Total parenteral nutrition [n (%)] | 85 (72.6%) | 65 (69.9%) | 20 (83.3%) | 0.188 |
Hypoproteinemia [n (%)] | 49 (41.9%) | 37 (39.8%) | 12 (50.0%) | 0.366 |
Surgery [n (%)] | 77 (65.8%) | 59 (63.4%) | 18 (75.0%) | 0.287 |
Abdominal | 39 (33.3%) | 32 (34.4%) | 7 (29.2%) | 0.627 |